natgillin/translations-raw huggingface dataset:
If more than one type of eye drop is being used, each one should be given at least five minutes apart.
Če bolnik uporablja več vrst kapljic za oko, je treba zdravila vkapati v razmiku najmanj 5 minut.
LUMIGAN is not recommended for patients less than 18 years old.
Zdravilo LUMIGAN ni priporočljivo za bolnike, mlajše od 18 let.
How does LUMIGAN work?
Kako zdravilo LUMIGAN deluje?
When intraocular pressure is raised, it causes damage to the retina (the light-sensitive membrane at the back of the eye) and to the optic nerve that sends signals from the eye to the brain.
Zvišan znotrajočesni tlak poškoduje mrežnico (membrana na zadnji strani zrkla, ki je občutljiva za svetlobo) in vidni živec, ki pošilja signale iz očesa v možgane.
The active substance in LUMIGAN, bimatoprost, is a prostaglandin analogue (a man-made copy of a natural substance, prostaglandin).
Zdravilna učinkovina zdravila LUMIGAN, bimatoprost, je prostaglandinski analog (umetno pripravljena kopija naravne snovi, prostaglandina).
In the eye, prostaglandin increases the drainage of the watery fluid (aqueous humour) out of the eyeball.
V očesu prostaglandin poveča odvajanje vodene tekočine (prekatne vodke) iz zrkla.
LUMIGAN acts in the same way and increases the flow of fluid out of the eye.
Zdravilo LUMIGAN deluje na enak način in poveča iztekanje tekočine iz očesa.
How has LUMIGAN been studied?
Kako je bilo zdravilo LUMIGAN raziskano?
LUMIGAN used on its own has been compared with timolol (a beta-blocker used to treat glaucoma) in two 12-month studies involving a total of 1,198 patients.
Samostojno uporabo zdravila LUMIGAN so primerjali s timololom (zaviralcem beta receptorjev, ki se uporablja za zdravljenje glavkoma) v 2 študijah, ki sta skupaj obsegali 1. 198 bolnikov in sta trajali 12 mesecev.
LUMIGAN has also been compared with latanoprost (another prostaglandin analogue used in glaucoma) in a six- month study involving 269 patients.
Zdravilo LUMIGAN so primerjali tudi z latanoprostom (drugim prostaglandinskim analogom, ki se uporablja za zdravljenje glavkoma) v šestmesečni študiji, ki je vključevala 269 bolnikov.
(44-20) 74 18 84 00 Fax (44-20) 74 18 84 16 E-mail: mail@emea. europa. eu http: / /www. emea. europa. eu ©EMEA 2007 Reproduction and/ or distribution of this document is authorised for non commercial purposes only provided the EMEA is acknowledged latanoprost in another study in 437 patients.
(44- 20) 74 18 84 00 Fax (44- 20) 74 18 84 16 E- mail: mail@ emea. europa. eu http: // www. emea. europa. eu ©EMEA 2007 Reproduction and/ or distribution of this document is authorised for non commercial purposes only provided the EMEA is acknowledged V eni študiji z 285 bolniki so primerjali učinkovitost dodatka zdravila LUMIGAN obstoječemu zdravljenju z zaviralcem beta receptorjev v obliki kapljic za oko in dodatka placeba (zdravila brez zdravilne učinkovine).
Eye pressure is measured in ‘ millimetres of mercury’ (mmHg).
Očesni tlak se meri v milimetrih živega srebra (mmHg).
What benefit has LUMIGAN shown during the studies?
Kakšne koristi je zdravilo LUMIGAN izkazalo med raziskavami?
LUMIGAN on its own was more effective than timolol at reducing eye pressure.
Zdravilo LUMIGAN je bilo v samostojni rabi za zniževanje očesnega tlaka učinkovitejše od timolola.
This effect was maintained after two or three years of treatment, with an average reduction in eye pressure of between 7.1 and 8.6 mmHg with LUMIGAN used once a day, compared with 4.6 to 6.4 mmHg with timolol.
Pri bolnikih, ki so uporabljali zdravilo LUMIGAN enkrat dnevno, je bilo povprečno znižanje očesnega tlaka od 7, 1 do 8, 6 mmHg, pri bolnikih, ki so uporabljali timolol, pa 4, 6 do 6, 4 mmHg.
LUMIGAN was also more effective than latanoprost, with patients using LUMIGAN achieving a reduction in eye pressure of 6.0 to 8.2 mmHg after six months of treatment compared with 4.9 to 7.2 mmHg with latanoprost.
Zdravilo LUMIGAN je bilo učinkovitejše tudi od latanoprosta, saj je bilo znižanje očesnega tlaka pri bolnikih, ki so uporabljali zdravilo LUMIGAN, po 6 mesecih zdravljenja 6, 0 do 8, 2 mmHg, pri bolnikih, ki so uporabljali latanoprost, pa 4, 9 do 7, 2 mmHg.
Adding LUMIGAN to existing treatment with a beta-blocker was more effective than continuing to use the beta-blocker on its own.
Dodatek zdravila LUMIGAN k obstoječemu zdravljenju z zaviralcem beta je bil učinkovitejši od nadaljnje samostojne rabe zaviralca beta receptorjev.
After three months, eye pressure was lowered by 7.4 mmHg in the group adding LUMIGAN, compared with 3.6 mmHg in the group adding placebo.
Po treh mesecih se je očesni tlak bolnikov, katerim so dodali zdravilo LUMIGAN, znižal za 7, 4 mmHg, očesni tlak bolnikov, katerim so dodali placebo, pa za 3, 6 mmHg.
LUMIGAN was at least as effective as latanoprost when added to beta-blocker treatment, with reductions in eye pressure of 8.0 and 7.4 mmHg, respectively, after three months.
Dodatek zdravila LUMIGAN zdravljenju z zaviralcem beta receptorjev (znižanje očesnega tlaka za 8, 0 mmHg) je bil po treh mesecih najmanj enako učinkovit kot dodatek latanoprosta (znižanje očesnega tlaka za 7, 4 mmHg).
What is the risk associated with LUMIGAN?
Kakšna tveganja so povezana z zdravilom LUMIGAN?
The most common side effects with LUMIGAN (seen in more than 1 patient in 10) are conjunctival hyperaemia (increased blood supply to the eye, leading to eye irritation and redness), growth of eyelashes and ocular pruritus (itchy eye).
Najpogostejši neželeni učinki zdravila LUMIGAN (opaženi pri več kot 1 bolniku od 10) so bili: konjunktivna hiperemija (zvišan dotok krvi v oko, kar povzroči draženje in rdečino očesa), rast trepalnic in srbenje očesa.
For the full list of all side effects reported with LUMIGAN, see the Package Leaflet.
Za celoten seznam neželenih učinkov, o katerih so poročali pri uporabi zdravila LUMIGAN, glejte Navodilo za uporabo.
LUMIGAN should not be used in people who may be hypersensitive (allergic) to bimatoprost or any of the other ingredients.
Zdravila LUMIGAN ne smejo uporabljati osebe, ki utegnejo biti preobčutljive za (alergične na) bimatoprost ali katerokoli drugo sestavino zdravila.
LUMIGAN contains benzalkonium chloride, which is known to discolour soft contact lenses.
Zdravilo LUMIGAN vsebuje benzalkonijev klorid, ki dokazano obarva mehke kontaktne leče.
Therefore, care should be taken by people who wear soft contact lenses.
Zdravila LUMIGAN zato ne smejo uporabljati bolniki, ki nosijo mehke kontaktne leče.
Why has LUMIGAN been approved?
Zakaj je bilo zdravilo LUMIGAN odobreno?
The Committee for Medicinal products for Human Use (CHMP) decided that LUMIGAN’ s benefits are greater than its risks for the reduction of elevated intraocular pressure in chronic open-angle glaucoma and ocular hypertension (as monotherapy or as adjunctive therapy to beta-blockers).
Odbor za zdravila za uporabo v humani medicini (CHMP) je sklenil, da so koristi zdravila LUMIGAN za zmanjšanje zvišanega znotrajočesnega tlaka pri kroničnem glavkomu odprtega zakotja in okularni hipertenziji (v monoterapiji ali kot adjuvantna terapija z zaviralci beta receptorjev) večje od z njim povezanih tveganj.
The Committee recommended that LUMIGAN be given marketing authorisation.
Odbor je priporočil odobritev dovoljenja za promet z zdravilom LUMIGAN.
Other information about LUMIGAN:
Druge informacije o zdravilu LUMIGAN:
The European Commission granted a marketing authorisation valid throughout the European Union for LUMIGAN to Allergan Pharmaceuticals Ireland on 8 March 2002.
Evropska komisija je dovoljenje za promet z zdravilom LUMIGAN, veljavno po vsej Evropski uniji, odobrila družbi Allergan Pharmaceuticals Ireland dne 8. marca 2002.
The marketing authorisation was renewed on 8 March 2007.
Dovoljenje za promet z zdravilom je bilo podaljšano 8. marca 2007.
The full EPAR for LUMIGAN is available here.
Celotno Evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo LUMIGAN je na voljo tukaj.
LUMIGAN 0.3 mg/ ml eye drops, solution
LUMIGAN 0, 3 mg/ ml kapljice za oko, raztopina
One ml of solution contains 0.3 mg bimatoprost.
En ml raztopine vsebuje 0, 3 mg bimatoprosta.
Excipient: benzalkonium chloride 0.05 mg/ ml.
Pomožna snov: benzalkonijev klorid 0, 05 mg/ ml
Colourless to slightly yellow solution.
Brezbarvna do rahlo rumena raztopina
Reduction of elevated intraocular pressure in chronic open-angle glaucoma and ocular hypertension (as monotherapy or as adjunctive therapy to beta-blockers).
Zmanjšanje zvišanega znotrajočesnega tlaka pri kroničnem glavkomu odprtega zakotja in okularni hipertenziji (v monoterapiji ali kot adjuvantna terapija z zaviralci beta receptorjev).
The dose should not exceed once daily as more frequent administration may lessen the intraocular pressure lowering effect.
Odmerjanje naj ne presega dajanja enkrat dnevno, kajti pogostejše vkapanje lahko zmanjša učinek zniževanja znotrajočesnega tlaka.
If more than one topical ophthalmic medicinal product is being used, each one should be administered at least 5 minutes apart.
Če uporabljate več kot eno lokalno očesno zdravilo, ju je potrebno vkapati v razmiku najmanj 5 minut.
Use in children and adolescents (under the age of 18):
Uporaba pri otrocih in mladostnikih (do 18 let starosti):
LUMIGAN has only been studied in adults and therefore its use is not recommended in children or adolescents.
LUMIGAN so preučevali le pri odraslih in zaradi tega njegova uporaba pri otrocih in mladostnikih ni priporočljiva.
Use in hepatic and renal impairment:
Uporaba pri okvarah jeter in ledvic:
LUMIGAN has not been studied in patients with renal or moderate to severe hepatic impairment and should therefore be used with caution in such patients.
Zdravila LUMIGAN niso preučevali pri bolnikih z ledvičnimi okvarami ali zmerno do hudo okvarjenimi jetri in ga je zato pri takšnih bolnikih potrebno previdno uporabljati.
In patients with a history of mild liver disease or abnormal ALT, AST and/ or bilirubin at baseline, LUMIGAN had no adverse effect on liver function over 24 months.
Pri bolnikih z anamnezo blage bolezni jeter ali nenormalnih vrednosti ALT, AST in/ ali celokupnega bilirubina, LUMIGAN v 24 mesecih ni imel neželenega učinka na delovanje jeter.
Before treatment is initiated, patients should be informed of the possibility of eyelash growth, darkening of the eyelid skin and increased iris pigmentation since these have been observed during treatment with LUMIGAN.
Pred zdravljenjem je potrebno bolnika poučiti in informirati o možni rasti trepalnic, temnenju kože veke in povečani pigmentaciji irisa, saj so to spremembe, ki so jih opazili med zdravljenjem z LUMIGANOM.
The change in iris pigmentation occurs slowly and may not be noticeable for several months.
Sprememba pigmentacije irisa se pojavlja počasi in je lahko ne zaznamo nekaj mesecev.
At 12 months, the incidence was 1.5% and did not increase following 3 years treatment.
Po 12 mesecih je bila incidenca 1, 5% in se ni povečala v naslednjih 3 letih zdravljenja.
LUMIGAN contains the preservative benzalkonium chloride, which may be absorbed by soft contact lenses.
LUMIGAN vsebuje konzervans benzalkonijev klorid, ki se lahko absorbira v mehke kontaktne leče.
Contact lenses should be removed prior to instillation and may be reinserted 15 minutes following administration.
Kontaktne leče je potrebno pred vkapanjem odstraniti in jih ponovno vstaviti 15 minut po vkapanju.
Benzalkonium chloride, which is commonly used as a preservative in ophthalmic products, has been reported to cause punctate keratopathy and/ or toxic ulcerative keratopathy.
Za benzalkonijev klorid, ki se običajno uporablja v očesnih zdravilih kot konzervans, obstajajo poročila, da povzroča točkasto keratopatijo in/ ali toksično ulcerozno keratopatijo.
Since LUMIGAN contains benzalkonium chloride, monitoring is required with frequent or prolonged use in dry eye patients or where the cornea is compromised.
Ker LUMIGAN vsebuje benzalkonijev klorid, je pri pogosti ali podaljšani uporabi potreben nadzor pri bolnikih s suhimi očmi ali kjer je okvarjena roženica.
LUMIGAN has not been studied in patients with compromised respiratory function and should therefore be used with caution in such patients.
LUMIGAN niso preizkušali pri bolnikih z oslabelim delovanjem respiratornega sistema, zato je pri teh bolnikih potrebna previdna uporaba.
In clinical studies, in those patients with a history of a compromised respiratory function, no significant untoward respiratory effects have been seen.
V kliničnih študijah pri bolnikih z anamnezo oslabelega delovanja respiratornega sistema ni bilo zaznati neželenih učinkov na respiratorni sistem.
LUMIGAN has not been studied in patients with heart block more severe than first degree or uncontrolled congestive heart failure.
LUMIGAN niso preučevali pri bolnikih s težjo obliko srčne blokade kot prve stopnje ali pri nekontroliranem kongestivnem srčnem popuščanju.
LUMIGAN has not been studied in patients with inflammatory ocular conditions, neovascular, inflammatory, angle-closure glaucoma, congenital glaucoma or narrow-angle glaucoma.
LUMIGAN niso preizkušali pri bolnikih z očesnimi vnetji, neovaskularnimi vnetji, glavkomu zaprtega zakotja, kongenitalnemu glavkomu ali glavkomu zoženega zakotja.
Cystoid macular oedema has been uncommonly reported (≥ 1/ 1000 to < 1/ 100) following treatment with LUMIGAN and should therefore be used with caution in patients with known risk factors for macular oedema (e. g. aphakic patients, pseudophakic patients with a torn posterior lens capsule).
Občasno (≥1/ 1000 do < 1/ 100) so poročali o cistoidnem makularnem edemu kot posledici zdravljenja z LUMIGANOM, zato ga potrebno pri bolnikih z znanimi dejavniki tveganja na makularne edeme (n. pr. afakični bolniki, psevdoafakični bolniki s poškodovano posteriorno lečno kapsulo) uporabljati previdno.
No interactions are anticipated in humans, since systemic concentrations of bimatoprost are extremely low (less than 0.2 ng/ ml) following ocular dosing.
Ker je sistemska koncentracija bimatoprosta pri lokalni uporabi na očeh izjemno nizka (manj kot 0, 2 ng/ ml), ni bilo zaznati interakcij pri človeku.
Bimatoprost is biotransformed by any of multiple enzymes and pathways, and no effects on hepatic drug metabolising enzymes were observed in preclinical studies..
Pri predkliničnih študijah ni bilo opaziti učinka na jetrne encime, ki metabolizirajo zdravila.
In clinical studies, LUMIGAN was used concomitantly with a number of different ophthalmic beta-blocking agents without evidence of interactions.
Pri kliničnih študijah so LUMIGAN uporabili sočasno s številnimi drugimi očesnimi zaviralci beta receptorjev brez dokazov o interakcijah.
Concomitant use of LUMIGAN and antiglaucomatous agents other than topical beta-blockers has not been evaluated during adjunctive glaucoma therapy.
Sočasna uporaba LUMIGANA in drugih zdravil proti glavkomu, poleg lokalnih zaviralcev beta receptorjev med adjuvantno terapijo glavkoma, ni bila raziskana.
Pregnancy There are no adequate data from the use of bimatoprost in pregnant women.
Nosečnost Ni zadostnih podatkov o uporabi bimatoprosta pri nosečnicah.
Animal studies have shown reproductive toxicity at high maternotoxic doses (see section 5.3).
Študije pri živalih so pri visokih maternotoksičnih odmerkih pokazale reproduktivno toksičnost (glejte poglavje 5. 3).
LUMIGAN should not be used during pregnancy unless clearly necessary.
Vkolikor ni nujno potrebno, LUMIGANA med nosečnostjo ni dovoljeno uporabljati.
3 Lactation It is not known if bimatoprost is excreted in human milk, however, this substance is excreted in rat milk after intravenous administration.
3 Dojenje Ni znano, ali se bimatoprost izloča v materino mleko pri človeku, vendar pa se izloča v mleko pri podganah pri intravenskem dajanju.
It is recommended that LUMIGAN is not used in nursing mothers.
Priporočamo, da se LUMIGANA ne uporablja pri doječih materah.
LUMIGAN has negligible influence on the ability to drive and use machines.
LUMIGAN ima zanemarljiv vpliv na sposobnost vožnje in upravljanja s stroji.
As with any ocular treatment, if transient blurred vision occurs at instillation, the patient should wait until the vision clears before driving or using machinery.
Tako kot pri ostalih zdravljenjih oči, če se po vkapanju pojavi začasno zamegljen vid, morajo bolniki počakati z vožnjo ali upravljanjem s stroji, dokler se vid ne zbistri.
In clinical studies, over 1800 patients have been treated with LUMIGAN.
V kliničnih študijah je bilo z LUMIGANOM zdravljenih prek 1800 bolnikov.
On combining the data from phase III monotherapy and adjunctive LUMIGAN usage, the most frequently reported treatment- related adverse events were: growth of eyelashes in up to 45% in the first year with the incidence of new reports decreasing to 7% at 2 years and 2% at 3 years, conjunctival hyperaemia (mostly trace to mild and thought to be of a non-inflammatory nature) in up to 44% in the first year with the incidence of new reports decreasing to 13% at 2 years and 12% at 3 years and ocular pruritus in up to 14% of patients in the first year with the incidence of new reports decreasing to 3% at 2 years and 0% at 3 years.
S kombinacijo podatkov iz III. faze monoterapije in adjuvantne terapije LUMIGANA so bila najpogostejša poročila o neželenih učinkih kot posledici zdravljenja: rast trepalnic pri do 45% v prvem letu s porastom števila novih poročil za do 7% pri 2 letih in 2% pri 3 letih, konjunktivna hiperemija (najpogosteje le blaga in domnevno nevnetnega izvora) pri do 44% v prvem letu s porastom števila novih poročil do 13% v 2 letih in 12% v 3 letih in okularni puritus pri do 14% bolnikov v prvem letu s porastom števila novih poročil do 3% v 2 letih in 0% v 3 letih.
Less than 9% of patients discontinued due to any adverse event in the first year with the incidence of additional patient discontinuations being 3% at both 2 and 3 years.
Manj kot 9% bolnikov je prekinilo zdravljenje zaradi kateregakoli neželenega učinka v prvem letu s 3% porastom števila prekinitev zdravljenja bolnikov v 2. in 3. letu.
The following undesirable effects definitely, probably or possibly related to treatment were reported during clinical trials with LUMIGAN.
V kliničnih preskušanjih LUMIGANA so poročali o naslednjih neželenih učinkih, ki so zagotovo, verjetno ali morda v povezavi z zdravljenjem.
With each frequency grouping, undesirable effects are presented in order of decreasing seriousness
Pri razvrščanju po pogostosti so neželeni učinki pri vsaki skupini navedeni v padajočem zaporedju, od bolj do manj resnih.
Infections and infestations Uncommon (≥ 1/ 1000 to < 1/ 100): infection (primarily colds and upper respiratory tract infections)
Infekcijske in parazitske bolezni Občasni (≥1/ 1000 do < 1/ 100): infekcije (najpogosteje prehladi in infekcije zgornjih dihal)
Nervous system disorders Common (≥ 1/ 100 to < 1/ 10): headache Uncommon (≥ 1/ 1000 to < 1/ 100): dizziness
Bolezni živčevja Pogosti (≥1/ 100 do < 1/ 10: glavobol Občasni (≥1/ 1000 do < 1/ 100): vrtoglavica
Eye disorders Very common (≥ 1/ 10): conjunctival hyperaemia, growth of eyelashes, ocular pruritus
Očesne bolezni Zelo pogosti (≥1/ 10): konjunktivna hiperemija, rast trepalnic, očesni pruritus
Common (≥ 1/ 100 to < 1/ 10): allergic conjunctivitis, asthenopia, blepharitis, cataract, conjunctival oedema, corneal erosion, eye discharge, eyelash darkening, eye pain, foreign body sensation, increased iris pigmentation, ocular burning, ocular dryness, ocular irritation, photophobia, superficial punctate keratitis, tearing, visual disturbance and worsening of visual acuity
Pogosti (≥1/ 100 do < 1/ 10): alergijski konjunktivitis, astenopija, blefaritis, katarakta, konjunktivni edem, erozija roženice, očesni izcedek, temnenje trepalnic, bolečine v očeh, občutek tujka v očesu, povečana pigmentacija irisa, pekoče oči, suhe oči, iritacije oči, fotofobija, superfacialni točkasti keratitis, solzenje, motnje v vidu in slabšanje ostrine vida
Uncommon (≥ 1/ 1000 to < 1/ 100): blepharospasm, cystoid macular oedema, eyelid retraction, iritis, retinal haemorrhage, uveitis.
Občasni (≥1/ 1000 do < 1/ 100): blefarospazem, cistoidni makularni edem, edem vek, retrakcija vek, iritis, retinalna hemoragija, uveitis.
Vascular disorders Common (≥ 1/ 100 to < 1/ 10): hypertension
Žilne bolezni Pogosti (≥1/ 100 do < 1/ 10): povišan krvni tlak
Skin and subcutaneous tissue disorders Common (≥ 1/ 100 to < 1/ 10): eyelid erythema, eyelid pruritus, pigmentation of periocular skin Uncommon (≥ 1/ 1000 to < 1/ 100): eyelid oedema, hirsutism.
Bolezni kože in podkožja Pogosti (≥1/ 100 do < 1/ 10): eritem vek, pruritus vek, pigmentacija obočesne kože Občasni (≥1/ 1000 do < 1/ 100): edem vek, hirzutizem
General disorders and administration site conditions Uncommon (≥ 1/ 1000 to < 1/ 100): asthenia, peripheral oedema
4 Splošne težave in spremembe na mestu aplikacije Občasni (≥1/ 1000 do < 1/ 100): astenija, periferni edem
4 Investigations Common (≥ 1/ 100 to < 1/ 10): liver function test abnormal
Preiskave Pogosti (≥1/ 100 do < 1/ 10): abnormalni testi delovanja jeter
If overdosage occurs, treatment should be symptomatic and supportive.
Če se pojavijo znaki prevelikega odmerjanja, naj bo zdravljenje simptomatsko in podporno.
If LUMIGAN is accidentally ingested, the following information may be useful: in two-week oral rat and mouse studies, doses up to 100 mg/ kg/ day did not produce any toxicity.
Če LUMIGAN pomotoma zaužijete, je lahko koristna naslednja informacija: v dvotedenskih študijah pri peroralnem zaužitju pri podganah in miših odmerki v koncentraciji do 100 mg/ kg/ dan niso povzročili toksičnosti.
This dose expressed as mg/ m2 is at least 70-times higher than the accidental dose of one bottle of LUMIGAN in a 10 kg child.
Ta odmerek, izražen kot mg/ m2, je najmanj 70- krat višji kot naključni odmerek ene plastenke LUMIGANA pri otroku, ki tehta 10 kg.
Pharmacotherapeutic group: other antiglaucoma preparations; ATC code:
Farmakoterapevtska skupina: drugi pripravki za zdravljenje glavkoma; Oznaka ATC:
The mechanism of action by which bimatoprost reduces intraocular pressure in man is by increasing aqueous humour outflow through the trabecular meshwork and enhancing uveoscleral outflow.
Mehanizem delovanja, pri katerem bimatoprost zmanjšuje povišan znotrajočesni tlak pri človeku, je s povečanjem iztekanja prekatne vodice skozi trabekularno omrežje in povečanje uveoskleralnega iztekanja.
Reduction of the intraocular pressure starts approximately 4 hours after the first administration and maximum effect is reached within approximately 8 to 12 hours.
Zmanjševanje znotrajočesnega tlaka se začne približno 4 ure po prvem vkapanju.
The duration of effect is maintained for at least 24 hours.
Največji učinek je dosežen v približno 8 do 12 urah in traja najmanj 24 ur.
Bimatoprost is a potent ocular hypotensive agent.
Bimatoprost je močno delujoča učinkovina za zmanjšanje očesnega pritiska.
It is a synthetic prostamide, structurally related to prostaglandin F2α (PGF2α), that does not act through any known prostaglandin receptors.
Je sintetični prostamid, strukturalno podoben prostaglandinu F2α (PGF2α), ki ne deluje s pomočjo kateregakoli znanega prostagladinskega receptorja.
During 12 months’ monotherapy treatment, versus timolol, mean change from baseline in morning (08:00) intraocular pressure ranged from -7.9 to -8.8 mm Hg.
Med 12 mesečnim zdravljenjem v monoterapiji v primerjavi s timololom, so povprečne spremembe z osnovne vrednosti znotrajočesnega tlaka zjutraj (08: 00) znašale med – 7, 9 do – 8, 8 mm Hg.
At any visit, the mean diurnal IOP values measured over the 12-month study period differed by no more than 1.3 mmHg throughout the day and were never greater than 18.0 mmHg.
Ob vsaki viziti so se povprečne vrednosti diurnalnega znotrajočesnega tlaka, merjene v več kot 12 mesečnem času študija, razlikovale za ne več kot 1, 3 mmHg preko dneva in niso bile nikoli višje kot 18, 0 mmHg.